Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Sutton
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Sutton, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC25 AstraZeneca25 Merck Sharp & Dohme LLC12 Novartis Pharmaceuticals10 Seagen, a wholly owned subsidiary of Pfizer10
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Sutton

225 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
London, Sutton, Birmingham, Cambridge, Glasgow, Liverpool, Manchester, Nottingham
2026-09-29
Recruiting
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT07665515Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epitopea Ltd
Phase 1
50
Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, Sutton
2026-09
Recruiting
GlaxoSmithKline
Phase 3
600
Sutton, Leicester, London
2026-06-04
Recruiting
AstraZeneca
Phase 3
420
Edinburgh, Hampshire, Leeds, London, Manchester, Nottingham, Oxford, Sutton
2026-05-05
Recruiting
Genentech, Inc.
Phase 1/2
260
Sutton
2026-04-29
Recruiting
BioNTech SE
Phase 3
736
Cambridge, London, Sutton
2026-04-22
Recruiting
Renaissance Pharma Ltd.
Phase 2/3
144
Southampton, Sutton
2026-03-30
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Birmingham, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield, Sutton
2026-03-17
Recruiting
AstraZeneca
Phase 1/2
180
Cambridge, London, Sutton
2026-03-17
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
London, Oxford, Sutton, Glasgow, Manchester
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Aberdeen, Middlesbrough, Norwich, Sutton, Cambridge, Cardiff, Guildford, London
2026-03-12
Recruiting
Hoffmann-La Roche
Phase 2
100
Sutton, Cardiff
2026-03-11
Recruiting
Incyte Corporation
Phase 3
700
Bristol, Cardiff, Leeds, London, Maidstone, Manchester, Sutton
2026-03-05
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Cambridge, Cottingham, Ipswich, London, Maidstone, Sutton
2026-02-17
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Canterbury, Cardiff, Dundee, London, Nottingham, Portsmouth, Sutton
2026-02-04
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
DrugsPomalidomide·Dexamethasone
CellCentric Ltd.
Phase 2
100
Withington, Sutton, Cardiff, Bebington, Edinburgh, London, Oxford, Southampton
2026-01-22
Recruiting
Boehringer Ingelheim
Phase 3
400
Cardiff, Edinburgh, London, Manchester, Sutton
2026-01-16
Recruiting
Janssen Research & Development, LLC
Phase 1
40
Manchester, Sutton
2026-01-14
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Cardiff, Glasgow, London, Newcastle upon Tyne, Preston, Sutton
2025-12-19
Recruiting
Janssen Research & Development, LLC
Observational
380
Bath, Cardiff, Eastbourne, Guildford, Heath Town, London, Manchester, Sutton
2025-12-03
Recruiting
GlaxoSmithKline
Phase 1
83
Leicester, London, Sutton
2025-12-03
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Cambridge, London, Chelsea, Sutton, Stoke-on-Trent, Nottingham, Wolverhampton
2025-11-30
Recruiting
Amgen
Phase 3
750
London, Sutton
2025-11-28
Recruiting
AstraZeneca
Phase 1
40
Newcastle upon Tyne, Sutton
2025-11-25
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Oxford, Aberdeen, Derby, Lincoln, London, Southampton, Sutton
2025-11-25
Recruiting
BioNTech SE
Phase 1/2
245
Leeds, London, Manchester, Newcastle upon Tyne, Sutton
2025-11-18
Recruiting
Boehringer Ingelheim
Phase 3
670
Cardiff, Leicester, Manchester, Sutton, Torquay
2025-11-07
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Sutton, London
2025-10-15
Recruiting
AstraZeneca
Phase 1/2
283
Cambridge, London, Plymouth, Sutton
2025-10-01
Recruiting
BioNTech SE
Phase 1/2
880
London, Newcastle upon Tyne, Sutton
2025-09-22
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Birmingham, London, Manchester, Sutton
2025-09-02
Recruiting
Amgen
Phase 1
434
London, Sutton
2025-07-31
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Birmingham, Cardiff, Glasgow, Liverpool, London, Oxford, Sheffield, Sutton
2025-07-21
Recruiting
BioNTech SE
Phase 1/2
482
London, Manchester, Sutton
2025-07-18
Recruiting
Janssen Research & Development, LLC
Phase 1
140
Manchester, Sutton
2025-07-07
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Oxford, Sutton, Windsor, London
2025-07-01
Recruiting
EXACT Therapeutics AS
Phase 2
25
Cambridge, Hammersmith, Sutton
2025-06-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
Birmingham, Newcastle upon Tyne, Cardiff, Sutton
2025-05-26
Recruiting
SecuraBio
Phase 3
124
Sutton, Glasgow, Leicester, London, Manchester, Nottingham, Oxford
2025-05-19
Active, closed
Boehringer Ingelheim
Phase 1
91
London, Sutton
2025-05-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Cambridge, London, Exeter, Birmingham, Northwood, Sutton, Devon
2025-05-13
Active, closed
Byondis B.V.
Phase 1
7
Manchester, Sutton
2025-05-07
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
London, Liverpool, Sutton, Manchester
2025-05-06
Recruiting
AbbVie
Phase 2
390
London, Oxford, Sutton, Manchester
2025-04-24
Recruiting
BioNTech SE
Phase 1/2
380
Cambridge, Cardiff, Leeds, London, Manchester, Sutton
2025-04-23
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
605
Brighton, Fulham, Sutton, London, Manchester
2025-04-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool
2025-04-09
Active, closed
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06459869Locally Advanced Rectal Cancer (LARC)
Akamis Bio
Phase 1
30
London, Sutton
2025-04-07
Recruiting
Bayer
Phase 1/2
450
Manchester, Sutton
2025-03-21
Recruiting
AstraZeneca
Phase 3
840
Cambridge, Coventry, Dundee, London, Manchester, Sutton
2025-03-01
Recruiting
Bayer
Phase 1
148
London, Glasgow, Sutton
2025-02-28
Recruiting
GlaxoSmithKline
Phase 2
120
Glasgow, Leeds West Yorkshire, London, Sutton
2025-02-18
Recruiting
Janssen Research & Development, LLC
Phase 1/2
190
Sutton
2025-02-06
Recruiting
BioNTech SE
Phase 3
621
Manchester, Chelsea, Sutton, Huddersfield, Newcastle upon Tyne, Nottingham, Oxford, Dundee
2025-02-03
Active, closed
Pfizer
Phase 3
1,035
Harlow, Truro, Maidstone, Taunton, Sutton, Coventry, Guildford, London
2025-01-06
Recruiting
Janssen Research & Development, LLC
Phase 2
480
Greater London, Liverpool, London, Manchester, Sutton, Torquay
2024-12-16
Active, closed
Amgen
Phase 3
707
Glasgow, London, Sutton
2024-12-09
Recruiting
Ryvu Therapeutics SA
Phase 2
178
Glasgow, Manchester, Plymouth, Sutton, Tooting
2024-12-05
Recruiting
OSE Immunotherapeutics
Phase 3
363
Leicester, Manchester, Metropolitan Borough of Wirral, Sutton, Aberdeen
2024-12-03
Recruiting
Genentech, Inc.
Phase 1
410
Edinburgh, London, Manchester, Sutton
2024-11-14
Recruiting
Novartis Pharmaceuticals
Phase 1
106
Sutton, Birmingham, Glasgow
2024-11-11
Recruiting
Bayer
Phase 1
104
Manchester, Sutton
2024-11-08
Recruiting
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc.
Phase 1
65
Sutton
2024-11-08
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton
2024-10-18
Active, closed
Merus B.V.
Phase 3
699
Cambridge, Cardiff, London, Manchester, Newcastle upon Tyne, Northwood, Southampton, Sutton
2024-09-25
Active, closed
Hoffmann-La Roche
Phase 3
338
Cambridge, Cottingham, Glasgow, Leeds, London, Nottingham, Sutton, Torquay
2024-09-23
Active, closed
Microbiotica Ltd
Phase 1
41
Brighton, Cambridge, Glasgow, London, Manchester, Newcastle, Sutton
2024-08-28
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
London, Manchester, Newcastle upon Tyne, Sutton
2024-08-22
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Birmingham, Newcastle upon Tyne, London, Sutton, Cardiff
2024-08-16
Recruiting
Carrick Therapeutics Limited
Phase 1/2
50
Manchester, Oxford, Sutton
2024-08-16
Recruiting
NovoCure GmbH
Phase 3
734
London, Leicester, Liverpool, Sutton
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 1
31
Sutton, London
2024-07-29
Active, closed
Graegis Pharmaceuticals Ltd
Phase 2
273
Sutton
2024-07-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
London, Sutton, Glasgow, Leeds, Manchester
2024-07-24
Recruiting
Amgen
Phase 3
450
Birmingham, Glasgow, London, Maidstone, Northwood, Sheffield, Sutton
2024-07-17
Recruiting
Boehringer Ingelheim
Phase 1/2
768
Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton
2024-06-28
Active, closed
Exelixis
Phase 2/3
600
London, Romford, Manchester, Sutton, Torquay
2024-06-07
Recruiting
CDR-Life AG
Phase 1
42
Sutton, Glasgow, London
2024-05-24
Active, closed
Syndax Pharmaceuticals
Phase 1
96
London, Sutton
2024-05-21
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
DrugsTucatinib·Disitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Sutton, London, Manchester
2024-05-20
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugsKeytruda·Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
410
Chelsea, Northwood, Newcastle upon Tyne, Sutton, Aberdeen, Cambridge, Manchester, Norwich
2024-05-14
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Bristol, London, Newcastle upon Tyne, Sheffield, Southampton, Sutton
2024-04-18
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc
Phase 1
383
Chelsea, Oxford, Sutton
2024-03-25
Recruiting
GlaxoSmithKline
Phase 3
864
Edinburgh, Gloucester, London, Nottingham, Sutton, Wolverhampton
2024-03-21
Recruiting
Verastem, Inc.
Phase 3
270
Glasgow, Cambridge, Edinburgh, Leicester, London, Manchester, Sutton
2024-03-18
Recruiting
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06217822Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Bayer
Phase 1
198
London, Sutton, Newcastle upon Tyne
2024-03-07
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
MacroGenics
Phase 1
250
Oxford, Sutton
2024-03-06
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
London, Glasgow, Manchester, Sutton
2024-02-21
Active, closed
Boehringer Ingelheim
Phase 3
428
Edinburgh, Leicester, London, Sutton
2024-02-09
Recruiting
Vividion Therapeutics, Inc.
Phase 1
280
London, Manchester, Sutton
2024-01-25
Active, closed
BicycleTx Limited
Phase 2
375
Bristol, Cambridge, London, Plymouth, Sutton
2024-01-24
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Aberdeen, London, Nottingham, Sutton, Torquay
2024-01-11
Recruiting
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06190899mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease
DrugsGedatolisib·Darolutamide
Celcuity Inc
Phase 1/2
54
Cambridge, Southampton, Sutton
2024-01-01
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
Truro, Plymouth, Bournemouth, Salisbury, Uxbridge, Sutton, Great Yarmouth, Romford
2023-12-28
Active, closed
AstraZeneca
Phase 3
760
Cambridge, Edgbaston, Glasgow, Scotland, London, Manchester, Sutton
2023-12-04
Active, closed
Genentech, Inc.
Phase 1
65
Cambridge, Leicester, London, Oxford, Sutton
2023-11-27
Recruiting
AstraZeneca
Phase 3
625
Cardiff, Chelsea, Leicester, Liverpool, London, Oxford, Surrey, Sutton
2023-11-23
Recruiting
Amgen
Phase 3
750
Birmingham, Inverness, London, Northwood, Nottingham, Sutton, Torquay, Truro
2023-11-16
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
DrugDisitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Sutton, London
2023-11-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
London, Sutton, Manchester, Metropolitan Borough of Wirral
2023-11-12
Active, closed
Bayer
Phase 1
232
Cambridge, London, Sutton
2023-09-20
Recruiting
Novartis Pharmaceuticals
Phase 4
700
Sutton, Barnet, Cambridge, Glasgow, Middlesbrough
2023-08-14
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Cambridge, Glasgow, Scotland, London, Sutton
2023-06-05
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Guildford, Bebington, London, Manchester, Sutton
2023-06-01
Active, closed
Janssen Research & Development, LLC
Phase 1/2
71
London, Newcastle, Sutton
2023-05-18
Active, closed
Gilead Sciences
Phase 1
182
London, Sutton
2023-05-11
Recruiting
Genentech, Inc.
Phase 1
210
Cambridge, Leicester, Manchester, Sutton
2023-05-02
Active, closed
Hoffmann-La Roche
Phase 2
204
London, Preston, Sutton
2023-04-13
Active, closed
GlaxoSmithKline
Phase 2
154
Leeds West Yorkshire, London, Sutton
2023-04-03
Active, closed
AbbVie
Phase 3
520
Cheltenham, London, Northwood, Southampton, Sutton, Manchester, Swansea
2023-03-15
Recruiting
Boehringer Ingelheim
Phase 1
66
London, Oxford, Sutton
2023-02-24
Recruiting
Jazz Pharmaceuticals
Phase 3
510
Cambridge, Glasgow, Liverpool, Manchester, Sutton, Newcastle upon Tyne, Leeds, London
2023-01-23
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
Exeter, Edinburgh, Bristol, Sutton, Coventry, London, Manchester, Taunton
2023-01-16
Active, closed
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a.
Phase 3
130
Dartford, Huddersfield, Leeds, London, Plymouth, Preston, Sutton
2022-12-29
Recruiting
Immunocore Ltd
Phase 3
540
Cambridge, Manchester, Birmingham, Leeds, London, Middlesex, Sutton
2022-12-19
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
London, Newcastle upon Tyne, Sutton
2022-12-13
Active, closed
Celcuity Inc
Phase 3
701
Bath, Cardiff, London, Manchester, Nottingham, Sutton
2022-12-08
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
DrugRamantamig
Janssen Research & Development, LLC
Phase 1
180
London, Sutton
2022-11-22
Active, closed
Bayer
Phase 1
284
London, Oxford, Sutton, Newcastle upon Tyne
2022-11-04
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Keytruda·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
London, Sutton
2022-10-25
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Newcastle upon Tyne, Glasgow, Sutton, Bristol, Cambridge, Leeds, London, Manchester
2022-10-24
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Blackpool, Dundee, London, Newcastle upon Tyne, Nottingham, Plymouth, Sutton, Wolverhampton
2022-10-13
Active, closed
Bayer
Phase 1
129
Manchester, Sutton
2022-10-11
Active, closed
AbbVie
Phase 2
125
London, Northwood, Nottingham, Taunton, Sutton, Manchester
2022-09-28
Active, closed
Kite, A Gilead Company
Phase 3
231
Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton
2022-09-22
Active, closed
AstraZeneca
Phase 3
594
Guildford, Metropolitan Borough of Wirral, Stevenage, Sutton
2022-09-15
Active, closed
Exelixis
Phase 3
901
Bristol, Birmingham, Edinburgh, London, Romford, Sutton
2022-09-07
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Birmingham, London, Newcastle upon Tyne, Sutton
2022-08-05
Recruiting
Step Pharma, SAS
Phase 1/2
180
Leicester, London, Manchester, Nottingham, Oxford, Plymouth, Sutton
2022-08-03
Recruiting
Nuvalent Inc.
Phase 1/2
840
Sutton, Edinburgh, London, Manchester
2022-06-09
Recruiting
ORIC Pharmaceuticals
Phase 1
275
Sutton
2022-06-01
Recruiting
Eli Lilly and Company
Phase 1
260
London, Sutton
2022-05-11
Active, closed
Verastem, Inc.
Phase 1/2
153
Leicester, London, Sutton
2022-04-12
Active, closed
AstraZeneca
Phase 3
1,035
Edinburgh, Glasgow, Guildford, Hackensack, London, Manchester, Southampton, Sutton
2022-03-25
Active, closed
GlaxoSmithKline
Phase 1
152
Manchester, Sutton
2022-03-22
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
London, Sutton, Manchester
2022-03-07
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Active, closed
Amgen
Phase 1/2
329
London, Sutton
2022-02-01
Active, closed
BicycleTx Limited
Phase 1/2
200
Sutton, Glasgow
2021-11-02
Recruiting
Hoffmann-La Roche
Phase 1
542
Cambridge, Cardiff, London, Manchester, Sutton
2021-10-22
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Blackpool, Dundee, London, Oxford, Plymouth, Sutton
2021-10-14
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
DrugPaclitaxel
Nurix Therapeutics, Inc.
Phase 1
345
Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford
2021-09-29
Recruiting
BeOne Medicines
Phase 1/2
246
Headington, London, Sutton, Truro
2021-09-16
Recruiting
Genentech, Inc.
Phase 1
186
London, Sutton
2021-07-26
Active, closed
Boehringer Ingelheim
Phase 1
554
London, Sutton
2021-07-02
Active, closed
Novartis Pharmaceuticals
Phase 3
469
Guildford, Sutton, Coventry, London, Middlesbrough
2021-06-15
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Sutton, Belfast, Cambridge, Glasgow, London, Middlesbrough
2021-06-09
Active, closed
Incyte Corporation
Phase 3
899
Aberdeen, Bath, Birmingham, Bristol, London, Nottingham, Sutton, Wolverhampton
2021-05-11
Active, closed
Hoffmann-La Roche
Phase 3
761
Cambridge, Edinburgh, London, Plymouth, Preston, Sheffield, Southampton, Sutton
2021-05-03
Active, closed
Incyte Corporation
Phase 3
654
Birmingham, Bristol, Leicester, London, Manchester, Middlesbrough, Sutton, Wolverhampton
2021-04-15
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Bristol, Nottingham, Windsor, London, Oxford, Newmarket, Sutton, Manchester
2021-04-05
Active, closed
ALX Oncology Inc.
Phase 2
189
London, Sutton
2021-04-02
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
London, Oxford, Sutton
2021-03-18
Active, closed
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Phase 3
455
London, Sutton
2021-02-25
Active, closed
Genmab
Phase 3
483
Birmingham, London, Norwich, Nottingham, Plymouth, Southampton, Sutton, Truro
2021-01-13
Active, closed
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT04579380Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
DrugsTucatinib·Herceptin·Fulvestrant·Trastuzumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
217
London, Sutton
2021-01-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester
2021-01-10
Active, closed
Pfizer
Phase 3
841
Newcastle upon Tyne, Sutton, Birmingham, London, Oxford
2020-12-21
Active, closed
Verastem, Inc.
Phase 2
225
Edinburgh, Glasgow, London, Manchester, Sutton
2020-12-21
Active, closed
AstraZeneca
Phase 1/2
702
Cambridge, Manchester, Oxford, Sutton
2020-11-12
Active, closed
Janssen Research & Development, LLC
Phase 1
158
Manchester, Sutton
2020-11-10
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Edinburgh, London, Sutton
2020-10-13
Active, closed
Hoffmann-La Roche
Phase 3
992
Brighton, Leicester, London, Maidstone, Peterborough, Plymouth, Sutton, Truro
2020-10-09
Active, closed
AstraZeneca
Phase 3
370
London, Manchester, Newcastle upon Tyne, Sutton
2020-10-02
Active, closed
GlaxoSmithKline
Phase 3
302
London, Plymouth, Southampton, Stoke-on-Trent, Sutton
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Edinburgh, London, Manchester, Nottingham, Sutton
2020-09-30
Active, closed
Janssen Research & Development, LLC
Phase 2
194
London, Sothampton, Sutton
2020-09-17
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Sutton, Glasgow, Manchester
2020-09-16
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
London, Manchester, Sutton
2020-08-18
Recruiting
Eisai Inc.
Phase 1/2
182
Belfast, Glasgow, Manchester, Preston, London, Northwood, Cardiff, Sutton
2020-08-06
Active, closed
AstraZeneca
Phase 3
1,012
Cambridge, Guildford, Manchester, Plymouth, Sutton, Whitchurch
2020-07-13
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
DrugsSigvotatug vedotin·Keytruda·Cisplatin·Carboplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Sutton, Birmingham, London
2020-06-08
Active, closed
AstraZeneca
Phase 2
452
Cambridge, Dundee, London, Manchester, Sutton
2020-06-03
Active, closed
AstraZeneca
Phase 3
818
Aberdeen, Bournemouth, Bristol, Cardiff, Cheltenham, London, Manchester, Sutton
2020-04-16
Active, closed
Eisai Inc.
Phase 1
31
London, Sutton
2020-04-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Cambridge, Edinburgh, Glasgow, London, Sutton, Gillingham, Manchester
2020-02-27
Active, closed
Daiichi Sankyo
Phase 1
115
London, Manchester, Sutton
2020-02-10
Recruiting
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
NCT03934372Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia
DrugPonatinib
Incyte Biosciences International Sàrl
Phase 1/2
70
Glasgow, Liverpool, Sutton
2020-01-29
Active, closed
Takeda
Phase 3
354
London, Sutton, Bebington, Leicester, Manchester
2020-01-10
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
161
Cambridge, Manchester, Newcastle upon Tyne, Sutton
2019-12-20
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Truro, Plymouth, Sutton, Cardiff, London
2019-11-13
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Sutton, Liverpool, London
2019-11-04
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Truro, Edinburgh, Birmingham, London, Manchester, Sutton
2019-10-02
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
2019-09-18
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Sutton
2019-09-17
Active, closed
BeOne Medicines
Phase 3
510
Abergavenny, Birmingham, Dudley, Sutton
2019-08-20
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide
CellCentric Ltd.
Phase 1/2
250
Sutton, Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester
2019-08-09
Active, closed
Janssen Research & Development, LLC
Phase 3
2,517
Bristol, Cardiff, Dundee, London, Preston, Sutton, Wakefield, Wolverhampton
2019-06-11
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
DrugsZanzalintinib·Avelumab·Tecentriq·Atezolizumab
Exelixis
Phase 1
325
London, Sutton, Preston
2019-03-20
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
DrugDurvalumab
AstraZeneca
Phase 1/2
50
Leeds, London, Sutton
2019-03-07
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
387
Sutton
2019-01-23
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Truro, Sutton, Cardiff, London, Nottingham, Oxford, Preston, Stoke-on-Trent
2018-12-07
Active, closed
AstraZeneca
Phase 1
396
Cambridge, Leeds, London, Manchester, Sutton
2018-10-11
Active, closed
Tesaro, Inc.
Phase 3
1,400
Glasgow, Metropolitan Borough of Wirral, Portsmouth, Sutton, Truro
2018-10-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Cambridge, London, Sutton, Manchester
2018-09-12
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
DrugEpcoritamab
Genmab
Phase 1/2
666
Manchester, Plymouth, Southampton, Sutton
2018-06-26
Active, closed
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
DrugsTisotumab Vedotin·Tivdak·Keytruda·Cisplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
350
London, Sutton
2018-06-25
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Aberdeen, London, Sutton, Cambridge, Coventry, Dundee, Leeds, Manchester
2018-06-21
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
890
Oxford, Sutton, London, Manchester
2018-05-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
By invitation
USWM CT, LLC
Phase 1
250
London, Manchester, Sutton
2018-04-09
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Bristol, London, Manchester, Plymouth, Sheffield, Southampton, Sutton
2018-03-23
Active, closed
Janssen Research & Development, LLC
Phase 2
136
Bath, London, Southampton, Sutton, Truro
2018-03-02
Active, closed
ModernaTX, Inc.
Phase 1
161
Dundee, Sutton, London
2017-08-14
Active, closed
Eisai Inc.
Phase 1
60
Glasgow, Manchester, Sutton, London
2017-07-27
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
London, Manchester, Sutton
2017-03-07
Active, closed
Celgene
Phase 1/2
466
Birmingham, Leeds, Oxford, Sutton
2016-10-14
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Manchester, Newcastle upon Tyne, Sutton
2016-05-24
Active, closed
Eli Lilly and Company
Phase 2
309
London, Manchester, Acton, Bebbington, Sutton
2016-05-19
Active, closed
AstraZeneca
Phase 1/2
264
Cambridge, Dundee, Glasgow, Greater London, London, Manchester, Newcastle upon Tyne, Sutton
2016-03-17
Active, closed
Tesaro, Inc.
Phase 1
729
Newcastle upon Tyne, Aberdeen, London, Manchester, Oxford, Sutton
2016-03-07
Active, closed
MedImmune LLC
Phase 1/2
383
London, Sutton
2016-02-22
Active, closed
Bayer
Phase 1/2
154
Sutton
2015-12-16
Active, closed
Taiho Oncology, Inc.
Phase 1/2
253
Leicester, Southampton, Oxford, Sutton, Birmingham, Glasgow, London, Manchester
2015-07-14
Active, closed
Janssen Research & Development, LLC
Phase 2
239
Blackburn, Dundee, Essex, London, Metropolitan Borough of Wirral, Plymouth, Sutton
2015-04-22
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Glasgow, Wonford, London, Sutton, Birmingham, Bristol
2014-12-17
Active, closed
Eli Lilly and Company
Phase 3
493
Bebbington, Cambridge, Manchester, Sutton
2014-11-06
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Gloucester, Southampton, Sutton, Harrow, Leeds, Cambridge, Liverpool, London
2014-11
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
Bristol, Cambridge, Coventry, London, Manchester, Oxford, Sutton, Withington
2014-10-31
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 1
57
Sutton
2014-07-09
Active, closed
AstraZeneca
Phase 3
510
Aberdeen, London, Manchester, Nottingham, Sutton, Wolverhampton
2013-09-25
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Birmingham, Cambridge, Coventry, Edinburgh, London, Manchester, Sutton
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Birmingham, Cambridge, Coventry, Edinburgh, London, Sutton
2013-08-26
Active, closed
AstraZeneca
Phase 1
197
Edinburgh, London, Manchester, Newcastle upon Tyne, Northwood, Oxford, Sutton
2008-10-27
Active, closed
AstraZeneca
Phase 1
58
Sutton
2007-03-08
Rows per page Showing 1–225 of 225
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-uk/city/sutton

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 10 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 225 of those studies with a site in Sutton.

How many clinical trials are recruiting in Sutton?

104 of the 225 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 120 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Sutton), 225 studies
PhaseStudiesRecruitingShare
Phase 3933741.3%
Phase 1552624.4%
Phase 1/2422818.7%
Phase 227812%
Phase 2/3532.2%
Phase 4210.9%
Observational110.4%

Most active sponsors

Lead sponsors with the most studies (Sutton)
Lead sponsorStudiesRecruiting
AstraZeneca257
Janssen Research & Development, LLC2511
Merck Sharp & Dohme LLC126
Novartis Pharmaceuticals105
Seagen, a wholly owned subsidiary of Pfizer103
Bayer84
Boehringer Ingelheim74
GlaxoSmithKline74
Amgen64
BioNTech SE66
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.